Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BAT1308 + BAT6021 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BAT1308 | BAT-1308|BAT 1308 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 133 | BAT1308 is a humanized monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in the restoration of T-cell mediated antitumor immune response (NCI Drug Dictionary). | |
| BAT6021 | BAT-6021|BAT 6021 | Immune Checkpoint Inhibitor 150 TIGIT Antibody 20 | BAT6021 is a monoclonal antibody that targets T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and prevents its interaction with its ligands, NECTIN2 (CD112) and PVR (CD155), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05073484 | Phase I | BAT6021 BAT1308 + BAT6021 | Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients | Terminated | AUS | 0 |